GeneDx Holdings Corp. Investor Alert: Lead Plaintiff Filing Deadline Approaches
Investors are reminded of the August 3 deadline to file as lead plaintiff in a class action lawsuit against GeneDx Holdings Corp. concerning alleged securities law violations.
NEW ORLEANS, July 10, 2026 – Investors are being alerted to an August 3, 2026 deadline to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS). The lawsuit concerns the purchase or acquisition of the company's shares between April 16, 2025, and May 4, 2026.
The complaint alleges that GeneDx and certain executives failed to disclose material information during the class period, violating federal securities laws. On May 4, 2026, the company reported its first-quarter 2026 financial results, revealing a drop in adjusted gross margin from 74% to 69%. GeneDx also missed revenue estimates for its exome and genome lines and lowered its full-year revenue guidance to $475–$490 million, down from a previous forecast of $540–$550 million.
Additionally, GeneDx disclosed a $31.2 million impairment loss related to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company. The company had promoted the acquisition as a means to expand its addressable market through scalable revenue streams. Following this news, GeneDx shares fell $33.42 per share, or 49.2%.
The case, Basma v. GeneDx Holdings Corp., No. 26-cv-00880, is pending in the U.S. District Court for the District of Connecticut. Interested investors can contact ClaimsFiler or the law firm Kahn Swick & Foti, LLC for more information on their legal options. ClaimsFiler provides information to retail investors regarding securities class actions and settlement recovery.